Dr. Issouf Fofana at Université d’Abobo-Adjamé | Côte d’Ivoire
Fofana Issouf, affiliated with Nangui Abrogoua University, focuses on computational drug design, molecular modeling, and pharmacokinetics-oriented inhibitor development against infectious and non-communicable diseases. His research encompasses structure-based and virtual screening approaches to identify and optimize small-molecule inhibitors targeting key enzymes of pathogens and human disease-relevant proteins. Notably, he has contributed to the development of inhibitors against Mycobacterium tuberculosis, including thymidylate kinase and enoyl-acyl carrier protein reductase, emphasizing favorable pharmacokinetic profiles for enhanced drug-likeness. His work extends to anticancer and antiviral applications, designing molecules targeting E6 papillomavirus proteins and SARS-CoV-2 3-chymotrypsin-like protease, employing in silico optimization and pharmacophore-based virtual screening strategies. Additionally, Fofana has explored the inhibition of human histone deacetylase 8 and acetylcholinesterase, contributing to potential therapeutic interventions for cancer and Alzheimer’s disease, respectively. His integrative approach combines computational chemistry, pharmacokinetics, and molecular docking to accelerate the discovery of bioactive compounds with improved efficacy and safety. Overall, his research demonstrates a consistent commitment to applying in silico methodologies for rational drug design, aiming to translate computational insights into effective therapeutic candidates against infectious, neurodegenerative, and oncological targets.
Citation Metrics (Google Scholar)
🟦 Citations 🟩 h-index 🟥 i10-index
Featured Publications